Whitehawk Therapeutics Advances Antibody-Drug Conjugate Research at AACR Annual Meeting 2026
- Whitehawk Therapeutics will present three preclinical abstracts at the AACR Annual Meeting, showcasing advancements in their antibody-drug conjugate portfolio.
- The company's next-generation ADCs demonstrated high potency and tumor regression at low dosing levels in xenograft studies.
- Whitehawk's innovative linker-payload enhances therapeutic benefits while minimizing side effects, positioning them as leaders in cancer treatment development.
Whitehawk Therapeutics Showcases Breakthroughs in Antibody-Drug Conjugate Development at AACR
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics firm, confirms its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting from April 17-22, 2026, in San Diego, CA. The company reveals that it will present three preclinical abstracts that illustrate significant advancements in its next-generation antibody-drug conjugate (ADC) portfolio. This marks a key moment for Whitehawk as it displays comprehensive proof-of-concept data for three of its ADC programs: HWK-007, HWK-016, and HWK-206. The focus lies on optimizing ADC designs to enhance treatment outcomes for cancer patients, tapping into the evolving landscape of oncological therapeutics.
The data presented showcases a promising therapeutic index for Whitehawk's next-generation TOP1i-based ADCs. David Dornan, PhD, Chief Scientific Officer, underscores the high potency of these ADCs, which demonstrates notable tumor regressions in xenograft studies at low dosing levels, specifically in the single-digit mg/kg range. This is a significant advancement, as it potentially positions Whitehawk's ADCs as best-in-class therapies. Moreover, non-human primate studies establish a high tolerability for these candidates, as evidenced by a highest non-severely toxic dose (HNSTD) observed at 60 mg/kg. Such findings not only validate the efficacy of the ADCs but also suggest a safer profile compared to many existing treatments.
The company's innovative approach utilizes a proprietary "carbon-bridge cysteine repairing" linker-payload, which is characterized by its low free payload in circulation, enhancing the therapeutic benefit while minimizing side effects. Whitehawk will present its findings through various formats at the AACR meeting: HWK-016 will be featured in a minisymposium, while HWK-007 and HWK-206 will be showcased in poster sessions. These presentations are significant to the clinical community and highlight the promise of emergent bioconjugation technologies. The detailed event schedule allows attendees to engage directly with the research, further solidifying Whitehawk’s position as a leader in the evolving oncological landscape.
In addition to the presentations, the abstracts for Whitehawk’s ADCs are already available on the AACR 2026 meeting website, showcasing the company's commitment to transparency and collaboration within the cancer research community. Attendees and investors can also access more information through Whitehawk’s Investors & News section, ensuring that stakeholders remain informed of the latest advancements in the company’s research initiatives. As Whitehawk continues to build on its research momentum, the AACR meeting represents a crucial platform for setting the stage for future developments in the fight against cancer.